Novartis India growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr2 yr
Revenue+6.3%−3.0%
EBITDA+40.1%+18.5%
Net Income+18.5%−1.2%
Total Assets+2.5%−1.8%
Total Equity+5.4%+0.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

NOVARTIND₹1,821.40

Novartis India Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+6.3-3.0
EBITDA+40.1+18.5
Net Income+18.5-1.2
Total Assets+2.5-1.8
Total Equity+5.4+0.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.